Sociedad Americana de Hirudoterapia

Gelin-2

Paralog of gelin identified in the Hirudo medicinalis sialotranscriptome — putative antiplatelet variant.

Preclínico / mecanísticoLast updated: 2026-05-26 · Reviewed by ASH Editorial Board
Molecular weight of Gelin-2 compared with other characterized leech-derived compoundsHementerin80 kDaHementin80 kDaHementin-Like Protein (HLP-1)80 kDaLeech Collagenase70 kDaHaemadipsa yanyuanensis Progr…70 kDaLeech Apyrase67 kDaCalin65 kDaHyaluronidase60 kDaAntithrombin III binding prot…58 kDaCollagenolytic Fibrinolysin55 kDaLeech Thrombospondin-Like Pro…50 kDaGelin-26 kDa
Molecular weight (kilodaltons) of Gelin-2 (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic
Page type
Compound profile
Evidence type
Paralog of gelin identified in the Hirudo medicinalis sialotranscriptome — putative antiplatelet variant.
Evidence level
In vitro
Drug vs leech
Purified natural compound
Safety domains
Bleeding

Clinical translation limit

Gelin-2's transcriptomic identification does NOT establish clinical efficacy. No FDA-approved derivative exists; functional differentiation from gelin is incomplete.

Molecular Profile

Category
Antiplatelet
Evidence tier
Preclinical
Molecular weight
6,000 Da
Source species
Hirudo medicinalis
Discovered
2018
Gelin-2 molecular structure

Biological Targets

  • → platelet aggregation (mechanism under characterization)

External Resources

    Related Antiplatelet Compounds

    Calin

    Anti-platelet adhesion protein that blocks von Willebrand factor–collagen binding.

    Saratin

    Anti-platelet adhesion protein blocking collagen-mediated platelet activation.

    Decorsin

    RGD-containing peptide inhibiting platelet GP IIb/IIIa receptor — eptifibatide ancestor.

    Ornatin

    RGD-peptide GP IIb/IIIa antagonist — sister molecule to decorsin from a different leech species.

    ← Back to Compound Reference

    Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.